Stockreport

Apollo Therapeutics Signs Exclusive Ex-China License From Sunshine Lake Pharma for Clinical-Stage FGF21 / GLP-1 Dual Receptor Agonist, a Therapeutic With Major Commercial Potential in Mult...

FTI Consulting, Inc.  (FCN) 
Last fti consulting, inc. earnings: 4/30 07:30 am Check Earnings Report
US:NYSE Investor Relations: ir.fticonsulting.com
PDF Both FGF21 and GLP-1 are clinically validated targets for cardio-metabolic disorders, liver disease, and related indications Dual agonist approach has potential to de [Read more]